Source: U.S. News & World Report
Thursday 3 November 2022 18:47:09
Pfizer on Thursday announced that the first participant in a trial to examine an influenza and COVID-19 combination vaccine has been dosed.
The early-stage trial will examine the shot’s safety, tolerability and ability to provoke an immune response, according to Pfizer and its partner BioNTech. The shot includes Pfizer’s updated COVID-19 shot that is designed to take on the omicron variant.
Annaliesa Anderson of Pfizer’s vaccine research and development said that such a shot “could simplify immunization practices against these two respiratory pathogens, potentially leading to better vaccine uptake for both diseases.”
“Even with existing seasonal influenza vaccines, the burden of this virus is severe across the world causing thousands of deaths and hospitalizations every year,” Anderson said in a statement.
The study will include 180 participants ranging from 18 to 64 years old.
“By combining both indications in one vaccine approach, we aim to provide individuals with an efficient way to receive immunization against two severe respiratory diseases with evolving viruses that require vaccine adaptation,” BioNTech CEO Ugur Sahin said in a statement.
The news comes as flu activity in the U.S. continues to increase. The first pediatric death from the flu was confirmed by the Centers for Disease Control and Prevention last week.
The CDC estimates that at least 6,900 people have been hospitalized with the flu so far this season, which is a level that hasn’t been recorded this early in the season going back over a decade.
Experts are concerned that low levels of immunity as well as the relaxation of COVID-19 mitigation measures could fuel a severe flu season as colder weather pushes more people indoors.